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Sclerosing peritonitis is a rare form of peritoneal inﬂammation with an often fatal outcome. The major risk factor of sclerosing
peritonitisisperitonealdialysistreatment butitcan alsooccur followingrenalorliver transplantationorbeassociatedwithcertain
drug treatment. This article gives an overview of reasons and treatment options for sclerosing peritonitis and shows a summery of
current literature about sclerosing peritonitis.
Sclerosing peritonitis (SP) is a rare form of peritoneal
inﬂammation which involves both the visceral and the
parietal surfaces of the abdominal cavity. SP is characterized
by a ﬁbrous thickening of the peritoneum and is reported to
complicate peritoneal dialysis, certain drugs, and infectious
peritonitis. SP was ﬁrst described in 1907 [1], with the term
“abdominal cocoon” being in use since 1978 [2].
Due to the low incidence and the relatively slow disease
progress, there is no valuable data with respect to the
comparative incidence of SP related to dialysis versus SP
without any known risk factor [3, 4]. Published data indicate
prevalence rates between 0.54% and 0.9% [5–7]. The etiol-
ogyofSPremainsunknownandpresumablyismultifactorial
[3, 4]. There is no distinct relationship between the renal
diseaseleadingtoendstagerenalfailureandthedevelopment
of SP.
The major risk factor for SP is peritoneal dialysis treat-
ment (PD) [8, 9]. Indeed, the utilization of the peritoneal
cavity for dialysis therapy is associated with an increased risk
of structural and functional damage to the peritoneal mem-
brane. PD-related risk factors such as duration of therapy,
poor biocompatibility of dialysis solutions, and peritonitis
are considered to be important for the development of SP,
withthedurationofPDbeingthemostrelevantsinglefactor.
SP usually occurs in patients receiving PD for more than 4 or
5 years and the incidence of SP in patients on PD treatment
forlessthan2yearsisverylow[6,7].Nonphysiologicdialysis
solutions may induce a chronic sterile inﬂammation in
the peritoneal cavity with upregulation of several cytokines
resulting in collagen synthesis by mesothelial cells and
ﬁbroblasts.Moreover,thehighconcentrationsofglucoseand
lactate as much as the low pH of the dialysis solutions and
bioincompatible substances directly damage the peritoneal
membrane. Alike bacterial or fungal peritonitis, they lead to
the loss of mesothelium and a decline in ﬁbrinolytic capacity
of the peritoneal membrane, and might thereby contribute
to the development of SP [7]. The largest observational
study published by Kim et al. [6] included 4.290 PD patients
followed from 1981 to 2002, 34 of whom developed SP,
correspondingtoanoverallprevalenceof0.79%.Themaleto
female ratio in these patients was 1:1, their median age was
44.5 years (range 19–66 years) and the median duration of
PD treatment until the diagnosis of SP was 64 months (range
9–144 months), with 23 of 34 patients (68%) having been
on PD for more than 4 years. Remarkably, 27 of the 34 SP
patients(79%)hadamedicalhistoryofperitonitis,including
two cases of fungal peritonitis, with a median of 6 and at
most 15 episodes of PD-related peritonitis ultimately leading
to catheter removal. 18 patients were diagnosed by clinical
and radiological methods, the remaining 16 were diagnosed2 Mediators of Inﬂammation
surgically. 11 patients were treated by laparotomy with
excision of the sclerosed peritoneum. The overall mortality
in SP patients was 24%, the mortality in patients who had
undergone surgical treatment was 43%.
Betablockersarealsosupposedtocontributetothedevel-
opment of SP [9], which has most commonly described in
association with practolol, but also metoprolol, propranolol
and atenolol [10, 11] .T h ep a t h o m e c h a n i s mi sn o te n t i r e l y
clear, but probably relates to the inhibition of surfactant
releasebybetablockers[9].Clinicalstudiesfoundahistoryof
corresponding medication in many patients with SP, yet the
factual signiﬁcance of this drug class for the development of
SP could not be clariﬁed [6]. Antibiotics used for treatment
of peritonitis are as well discussed to be a risk factor for SP
[12].
Clinical signs of patients developing SP while on pe-
ritoneal dialysis therapy are ultraﬁltration and clearance
failure. Furthermore, small bowel obstruction due to encap-
sulation, adhesions, and mural ﬁbrosis with anorexia, nau-
sea, and vomiting is frequently observed and ultimately
entails malnutrition (Table 1)[ 9]. Following termination of
PD treatment, patients with SP often develop ascites [13].
Histopathologic examination reveals ﬁbrosis of the entire
peritoneum with substantial thickening. This diﬀers from
simple sclerosis, which is also found in patients with ascites
or peritoneal dialysis and is usually not associated with a
clinically relevant disease progress [14].
T h e r ea r es o m er e p o r t so fS Pa sl a t es e q u e l a eo fP D ,
typically occurring in patients who had previously under-
gone successful renal transplantation [15]. Adamidis et al.
reported a case of a former PD patient who presented 2
years after renal transplantation with abdominal discomfort,
vomiting, and malnutrition due to SP. Despite the initial
conservative treatment, for persistence of symptoms he
underwent surgical treatment later on and recovered without
any further complication [16]. Bowers et al. reported 3 cases
of SP in former, meanwhile successfully transplanted PD
patients. Each of these patients suﬀered from a mechanical
small bowel obstruction secondary to a densely ﬁbrosing
and encasing peel of reactive tissue visibly diﬀerent from the
usual postoperative adhesions [17]. Morrow et al. reported
the case of a 55-year-old woman with end-stage renal disease
secondarytosystemiclupuserythematodeswhohadreceived
two renal transplants within 15 years; between the two
transplantations she had been on PD for 5 years. Following
her second successful kidney transplant, she presented
with persistent nausea and vomiting and was diagnosed
to have SP by CT scan. Due to failure of conservative
management she underwent exploratory laparotomy with
extensive lysis of adhesions and the postoperative course was
complicated by intolerance to feedings. 3 months later, a
second laparotomy had to be performed due to obstruc-
tion of the proximal jejunum. Intraoperative ﬁndings were
similar to the prior ones. Extensive lysis of adhesions and
Billroth II gastrojejunostomy bypass is done, and the patient
recovered tolerating a regular diet [15]. Table 2 summarizes
the publications relating to patients with SP following renal
transplantation, the respective therapy, and patient survival.
From the sporadic case reports, however, no preferential
Table 1: Clinical characteristic of sclerosing peritonitis (SP).
Abdominal pain
Nausea
Vomiting
Weight loss
Loss of ultraﬁltraion (in PD patients)
Blood-stained dialysate (in PD patients)
Table 2: Sclerosing peritonitis after kidney transplantation.
No. of cases Therapy Survival:death
Bowers et al. 3 Surgery 3:0
Clin transplant 1994
Morrow et al. 1 Surgery 1:0
Dig Dis Sci 2011
Adamidis et al. 1 Surgery 1:0
Ren Fail 2011
association with determinate immunosuppressive regimens
could be inferred nor be corroborated by any other evidence.
Anyway, even though being extremely rare, SP has to
be included in the diﬀerential diagnosis of every renal
transplant patient with prior PD treatment who presents
with unexplained malnutrition and symptoms of abdominal
obstruction.
SP has been also described in association with other
diseases and as an idiopathic form [18]. The idiopathic
form predominantly occurs in adolescent females and a
possible relationship to retrograde menstruation has been
discussed [19, 20]. SP has also been reported in patients with
ventriculoperitoneal shunts [21]. Moreover, patients with
end-stage liver disease waiting for liver transplantation are at
a higher risk for developing SP. With continuous peritoneal
irritation from ascites and recurrent spontaneous bacterial
peritonitis, these patients suﬀer from two independent
conditions identiﬁed as risk factors for SP. SP has also been
reported in patients after liver transplantation. The typical
symptoms are abdominal pain, refractory ascites, bowel
obstruction,andmalnutrition[22–24].Inalargeprospective
study including 1.800 liver transplant recipients, Maguire et
al. reported on 5 patients aged 16 to 57 years who developed
SP after liver transplantation. None of these patients had a
peritoneal-venous shunt or had undergone peritoneal dialy-
sis. All 5 patients developed fever as early as 66 ± 21 hours
posttransplant, with conﬁrmation of bacterial peritonitis in
two patients and additional symptoms including epigastric
discomfort and intermittent vomiting occurring 12 ± 10
days later. While abdominal CT consistently showed marked
ascites conﬁned to deﬁnite areas of the abdomen, ultrasound
and intestinal contrast studies were not diagnostic. All
patientsunderwentanearlysecondlaparotomywithremoval
of an abdominal cocoon membrane. 4 of 5 patients survived
without long-term sequelae [22]. Mekeel et al. reported on 3
patientssuﬀeringfromSPafterlivertransplantation,namely,
two 42- and 62-year-old males with end-stage liver disease
due to hepatitis C infection without signiﬁcant other pastMediators of Inﬂammation 3
Table 3: Sclerosing peritonitis after liver transplantation.
No. of
cases Therapy Survival:death
Maguire et al. 5 Surgery 4:1
American Journal of Surgery 2001
Lin et al. 1 Surgery 1:0
World Journal Gastroenterol 2005
Mekeel et al. 3 Surgery 0:3
Liver Transplantation 2009
medical or surgical history and a 59-year-old alcoholic. All 3
patientshadmassiverefractoryasciteswithepisodesofspon-
taneous bacterial peritonitis prior to transplantation. Two
patients had evidence of a ﬁbrous peel already at the time
of transplantation. Postoperatively, all 3 patients continued
to have refractory ascites and episodes of peritonitis, along
with partial small bowel obstructions, abdominal pain, and
malnutrition. Beyond that, in two patients a constriction of
the graft, including biliary as well as inferior vena cava and
outﬂow obstruction occurred [23]. Lin et al. reported on
a patient with hepatitis-B-related hepatocellular carcinoma
and a prior peritoneal-venous shunt who developed SP with
smallbowelobstructiontwoweeksafterlivertransplantation
[24]. Accordingly, not only SP apparently occurs rather
early in recipients of liver transplants, but its diagnosis
proves to be diﬃcult. Table 3 summarizes the publications
relating to patients with SP following liver transplantation,
the respective therapy, and patient survival.
At last, SP has been observed in children who had
previously undergone intestinal transplantation; it is charac-
terized by progressive serositis as well as ﬁbrous changes of
the intestinal allograft mesentery and serosa with progres-
sive contraction culminating in intestinal obstruction. The
native intestinal tract is always spared. The causes of SP
associated with intestinal transplantation are not completely
understood. No distinct risk factors as cold ischemia time
or severity of rejection could be identiﬁed. In an adult
patient, sclerosing mesenteritis ascribed to a vascular form
of antibody-mediated rejection has been reported after a
combined liver-intestine transplantation; therefore, chronic
rejection may be considered as a trigger for the development
of SP in intestinal transplant recipients. Macedo et al.
retrospectively reviewed the medical records of 121 children
who underwent intestinal transplantation between 1990 and
2003; in this cohort, three children (2.4%) suﬀered from
distal ileal obstruction of the allograft intestine secondary
to SP. The indication for their intestinal transplantation
was intestinal failure secondary to gastroschisis in two
patients and midgut volvulus in one patient. All patients
had become independent of total parenteral nutrition and
were asymptomatic until the diagnosis of SP. The mean time
to presentation with symptoms of SP was 6.6 years (range
5.3–8years)fromintestinaltransplantation.Laparotomywas
performed in all three patients and showed serositis, dense
ﬁbrousadhesions, and acontractedmesentery. Inallpatients
adhesiolysis and segmental resection of the distal ileum were
performed. Two patients died 2.5 and 3, respectively, years
after transplantation [25].
The diagnosis of SP is made clinically, radiographically,
or by laparotomy. Characteristic radiographic ﬁndings can
be visualized on small bowel follow-through series or CT
imaging. CT scans typically show small bowel congregatedin
the center of the abdomen, thickened peritoneum, or large
locular ﬂuid collections. In addition, a delayed transit of
c o n t r a s tc a nb eo b s e r v e do nﬂ u o r o s c o p y[ 15, 26–28].
There is no expert agreement on whether the treatment
ofchoiceshouldbesurgicalorconservative.Asobviousfrom
thelowincidenceofSP,therearenorespectiveclinicalstudies
comparing the diﬀerent therapeutical approaches, and expe-
rience is limited to case reports. Treatment of PD patients
with SP includes cessation of PD therapy and conversion to
hemodialysis. Bowel rest and total parenteral nutrition seem
to alleviate symptoms substantially. Medical treatment reg-
imens based on corticosteroids and methotrexate have been
recommended[29,30];foritsknowneﬀectsonotherﬁbrotic
diseases, including retroperitoneal ﬁbrosis and desmoid
tumors, tamoxifen has been adopted as therapeutic agent in
SPaswell[31].However,thereareminimaldatasupportinga
positive eﬀect of any of the cited medical treatment options.
Surgical treatment is exclusively recommended for patients
suﬀering from intestinal obstruction [6]. The mortality of
SP has been reported as high as 24% and may attain
60% in patients who is managed operatively [6]d u et o
perioperative complications like anastomosis insuﬃciency,
intraabdominal infections, and enterocutaneous ﬁstulas.
In conclusion, SP is a rare but serious complication af-
fecting mainly patients on PD treatment. SP is a potentially
late sequela of PD and can be found as well in patients
after liver or intestinal transplantation without a history
of PD; hence, it should be included in the diﬀerential
diagnosis of every case of unexplained malnutrition and
abdominal obstruction, especially in patients after solid
organ transplantation.
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